FAQ on Oragenics Inc.'s Phase II Concussion Trial Approval in Australia

What is ONP-002?

ONP-002 is Oragenics Inc.’s proprietary neuroprotective therapy for mild traumatic brain injury (mTBI), or concussion, which has shown safety in Phase I and efficacy in preclinical models by reducing inflammation, oxidative stress, and brain swelling.

Why is the approval from Australia’s HREC significant for Oragenics Inc.?

The approval allows Oragenics Inc. to initiate patient enrollment for a Phase II clinical trial of ONP-002 in Australia, marking a key step toward expanding the ONP-002 program internationally, with potential sites in New Zealand under consideration.

How does ONP-002 work?

ONP-002 is a non-invasive intranasal formulation designed to treat concussions by reducing inflammation, oxidative stress, and brain swelling, as demonstrated in preclinical models and Phase I trials.

When will patient enrollment for the Phase II trial begin?

Patient enrollment for the Phase II trial of ONP-002 is expected to begin as early as Q2 2025 at Level 1 trauma emergency departments in Australia.

Where will the Phase II trial take place?

The Phase II trial will take place at Level 1 trauma emergency departments in Australia, where concussed patients are often treated, with enrollment sites in New Zealand also under consideration.

Who is leading Oragenics Inc.?

Janet Huffman is the CEO of Oragenics Inc., a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases.

What are the implications of this trial for concussion treatment?

The trial represents a significant advancement in the development of non-invasive treatments for concussions, potentially offering a new therapeutic option to reduce inflammation, oxidative stress, and brain swelling associated with mild traumatic brain injury.

How can I find more information about Oragenics Inc. and its trials?

For more information about Oragenics Inc. and its trials, visit the company’s website at www.Oragenics.com or the latest news and updates relating to OGEN at https://ibn.fm/OGEN.